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The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread 
throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and 
B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing 
antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited 
antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing 
titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. 
B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to 
monoclonal antibodies to the receptor-binding domain and the amino-terminal 
domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both 
airway organoid and human airway epithelial systems, associated with B.1.617.2 spike 
being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike 
protein was able to mediate highly efficient syncytium formation that was less 
sensitive to inhibition by neutralizing antibody, compared with that of wild-type 
spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry 
than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more 
than 130 SARS-CoV-2-infected health care workers across three centres in India during 
a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine 
effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible 
residual confounding. Compromised vaccine efficacy against the highly fit and 
immune-evasive B.1.617.2 Delta variant warrants continued infection control 
measures in the post-vaccination era.
India’s first wave of SARS-CoV-2 infections in mid-2020 was relatively 
mild and was controlled by a nationwide lockdown. Following the easing 
of restrictions, India has seen expansion in cases of coronavirus disease 
2019 since March 2021 with widespread fatalities and a death toll of 
more than 400,000. Cases of the B.1.1.7 Alpha variant, introduced by 
travel from the UK in late 2020, expanded in the north of India, and it 
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is known to be more transmissible than previous versions of the virus 
bearing the D614G spike substitution, while maintaining sensitivity 
to vaccine-elicited neutralizing antibodies2,3. The B.1.617 variant was 
first identified in the state of Maharashtra in late 20204, spreading 
throughout India and to at least 90 countries.
The first sublineage to be detected was B.1.617.1 (ref. 1), followed by 
B.1.617.2, both bearing the L452R spike receptor-binding motif (RBM) 
substitution also observed in B.1.427/B.1.429 (refs. 1,5). This alteration 
was previously reported to confer increased infectivity and a modest 
loss of susceptibility to neutralizing antibodies6,7. The B.1.617.2 Delta 
variant has since dominated over B.1.617.1 (Kappa variant) and other 
lineages including B.1.1.7, although the reasons remain unclear.
Delta variant and neutralizing antibodies
We first plotted the relative proportion of variants in new cases of 
SARS-CoV-2 in India since the start of 2021. Although B.1.617.1 emerged 
earlier, the Delta variant B.1.617.2 has become more dominant (Fig. 1a). We 
hypothesized that B.1.617.2 would exhibit immune evasion to antibody 
responses generated by previous SARS-CoV-2 infection. We used sera 
from 12 individuals infected during the first UK wave in mid-2020. These 
sera were tested for their ability to neutralize a B.1.617.2 viral isolate, in 
comparison with a B.1.1.7 variant isolate and a wild-type (WT) Wuhan-1 
virus bearing D614G in spike. The Delta variant contains several spike 
alterations that are located at positions within the structure that are pre-
dicted to alter its function (Fig. 1b). We found that the B.1.1.7 virus isolate 
was 2.3-fold less sensitive to the sera than the WT, and that B.1.617.2 was 
5.7-fold less sensitive to the sera (Fig. 1c). Importantly, in the same assay, 
the B.1.351 Beta variant that was first identified in South Africa demon-
strated an 8.2-fold loss of neutralization sensitivity relative to the WT.
We used the same B.1.617.2 live virus isolate to test susceptibility 
to vaccine-elicited serum neutralizing antibodies in individuals fol-
lowing vaccination with two doses of ChAdOx1 or BNT162b2. These 
experiments showed a loss of sensitivity for B.1.617.2 compared with 
WT Wuhan-1 bearing D614G of around eightfold for both sets of vac-
cine sera and reduction against B.1.1.7 that did not reach statistical 
significance (Fig. 1d). We also used a pseudotyped virus (PV) system to 
test the neutralization potency of a larger panel of 65 vaccine-elicited 
sera, this time against B.1.617.1 as well as B.1.617.2 spike compared with 
Wuhan-1 D614G spike (Fig. 1e). Comparison of demographic data for 
vaccinees showed similar characteristics (Extended Data Table 1). The 
mean geometric mean titre (GMT) against Delta variant spike PV was 
lower for ChAdOx1 than for BNT162b2 (GMT 654 versus 3,372, P < 0001, 
Extended Data Table 1).
We investigated the role of the B.1.617.2 spike as an escape mechanism 
by testing 33 spike-specific monoclonal antibodies with an in vitro PV 
neutralization assay using Vero E6 target cells expressing transmem-



































































































































































































































Fig. 1 | Rapid expansion of Delta variant B.1.617.2 cases in India and reduced 
sensitivity to neutralizing antibodies from sera derived following 
infection and vaccination. a, Proportion of lineages in incident cases of 
SARS-CoV-2 in India 2020–2021. b, Surface representation of the SARS-CoV-2 
B.1.671.2 spike trimer (PDB: 6ZGE). Red, L19R; green, del157/158; blue, L452R; 
yellow, T478K. The white dotted box indicates the location of the D950N 
substitution (orange). c, Neutralization of the Delta variant by convalescent 
human serum from mid-2020. Fold change in serum neutralization 
of 100 TCID50 of B.1.17 (Alpha), B.1.351 (Beta) and B.1617.2 (Delta) variants 
relative to WT (IC19); n = 12. Shown is the ID50, the serum dilution required for 
50% virus inhibition, expressed as GMT (from technical replicates) with s.d. d, 
Neutralization of B.1617.2 live virus by sera from vaccinated individuals (n = 10 
ChAdOx1 or n = 10 BNT12b2), compared with B.1.1.7 and Wuhan-1 WT. The graph 
presents the average of two independent experiments. e, Neutralization of 
B.1.617 spike PV and WT (Wuhan-1 D614G) by vaccine sera (n = 33 ChAdOx1 or 
n = 32 BNT162b2). The data are representative of two independent experiments 
each with two technical replicates. *P < 0.05, **P < 0.01, ****P < 0.0001 
(Wilcoxon matched-pairs signed rank test); NS, not significant.
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spike or the B.1.617.2 spike (Extended Data Fig. 1 and Extended Data 
Table 2). We found that all three amino-terminal domain monoclonal 
antibodies (100%) and four out of nine (44%) non-RBM monoclonal 
antibodies completely lost neutralizing activity against B.1.617.2. Within 
the RBM-binding group, 16 out of 26 monoclonal antibodies (61.5%) 
showed a marked decrease (2- to 35-fold-change reduction) or complete 
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Fig. 2 | Delta variant live virus replication kinetics and spike-mediated 
infectivity. a–d, Live virus replication comparing B.1.1.7 with B.1.617.2. Calu-3 
cells were infected with variants at an MOI of 0.1. a, Viral loads measured by 
qPCR in cell lysates. b, Viral protein levels in cell lysates. c, d, Live virus 
produced from infected Calu-3 cell supernatants was collected and used to 
infect permissive Vero E6 ACE2/TMPRSS2 cells to measure viral loads (c) or 
TCID50 ml
−1 (d). e, f, Virus replication kinetics in the HAE system. g, Live virus 
replication in airway epithelial organoid cultures. Airway epithelial organoids 
were infected with the SARS-CoV-2 variants B.1.1.7 and B.1.617.2 at an MOI of 1. 
Cells were lysed and total RNA was isolated. qPCR was used to determine the 
number of copies of the nucleoprotein gene in cells and the infectivity of 
cell-free virus measured by infection of Vero E6 ACE2/TMPRSS2 cells. The data 
are representative of two independent experiments. dpi, days post-infection. 
h, i, Western blots of PV virions (h) and cell lysates (i) of 293T producer cells 
following transfection with plasmids expressing lentiviral vectors and 
SARS-CoV-2 S B.1.617.1 and Delta variant B.1.617.2 versus WT (Wuhan-1 with 
D614G), probed with antibodies to HIV-1 p24 and SARS-Cov-2 S2. j, Calu-3 cell 
entry by spike B.1.617.2 and B.1.617.1 versus WT D614G parental plasmid PVs. 
The data are representative of three independent experiments. k, Growth 
kinetics of B.1.617.1 and B.1.617.2 variants. Viral isolates of B.1.617.1 and B.1.617.2 
were inoculated into Calu-3 cells, and viral RNA in the culture supernatant was 
quantified by real-time RT–PCR. The TCID50 of released virus in supernatant 
was measured over time. Assays were performed in quadruplicate. NS, not 
significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The data are 
representative of two independent experiments. Uninfected cells are 
represented by a minus symbol. NP, nucleocapsid protein.
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loss (>40-fold-change reduction) of neutralizing activity to B.1.617.2 
(Extended Data Fig. 1). Among five clinical-stage RBM monoclonal anti-
bodies tested, bamlanivimab did not neutralize B.1.617.2. Imdevimab, 
part of the REGN-COV2 therapeutic dual antibody cocktail8, displayed 
reduced neutralizing activity (Extended Data Fig. 1).
SARS-CoV-2 Delta variant replication
We first infected a lung epithelial cell line, Calu-3, comparing B.1.1.7 and 
B.1.617.2 (Fig. 2a–d). We observed a replication advantage for B.1.617.2 
(Fig. 2a, b), as well as an increase in released virions from cells (Fig. 2c, 
d). Next we tested B.1.1.7 against two separate isolates of B.1.617.2 in a 
human airway epithelial (HAE) model9. In this system we again observed 
that both B.1.617.2 isolates had a significant replication advantage 
over B.1.1.7 (Fig. 2e, f). Finally, we infected primary three-dimensional 
airway organoids10 (Fig. 2g) with B.1.617.2 and B.1.1.7 virus isolates, 
noting a significant replication advantage for B.1.617.2 over B.1.1.7. 
These data clearly support the higher replication rate and therefore 
transmissibility of B.1.617.2 over B.1.1.7.
In the aforementioned experiments, we noted a higher proportion of 
intracellular B.1.617.2 spike in the cleaved state, compared with B.1.1.7 
(Fig. 2b). We next ran western blots on purified virions probing for 
spike S2 and nucleoprotein, revealing B.1.617.2 spike predominantly in 
the cleaved form, in contrast to that in B.1 and B.1.1.7 (Extended Data 
Fig. 2a, b).
B.1.617.2 spike–mediated cell fusion
The plasma membrane route of entry, and indeed transmissibility in 
animal models, is critically dependent on the polybasic cleavage site 
between S1 and S2 (refs. 9,11,12) and cleavage of spike before virion release 
from producer cells. Alterations at P681 in the polybasic cleavage site 
have been observed in multiple SARS-CoV-2 lineages, most notably in 
the B.1.1.7 Alpha variant13. We previously showed that B.1.1.7 spike, bear-
ing P681H, had significantly higher fusogenic potential than a D614G 
Wuhan-1 virus13. Here we tested B.1.617.1 and B.1.617.2 spike using a split 
GFP system to monitor cell–cell fusion (Extended Data Fig. 2c–g). The 
B.1.617.1 and B.1.617.2 spike proteins mediated higher fusion activity and 
syncytium formation than WT, probably mediated by P681R (Extended 
Data Fig. 2f, g). We next titrated sera from ChAdOx1 vaccinees and 
showed that indeed the cell–cell fusion could be inhibited in a manner 
















































Fig. 3 | SARS-CoV-2 B.1.617.2 infection in vaccinated HCWs.  
a–c, Maximum-likelihood phylogenies of vaccine breakthrough SARS-CoV-2 
sequences among vaccinated HCWs at three centres. Phylogenies were 
inferred with IQTREE2 with 1,000 bootstrap replicates. SNPs, single nucleotide 
polymorphisms.
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of cells (Extended Data Fig. 2h). Hence, B.1.617.2 may induce cell–cell 
fusion in the respiratory tract and possibly higher pathogenicity even 
in vaccinated individuals with neutralizing antibodies.
B.1.617.2 spike–mediated cell entry
We tested single-round viral entry of B.1.617.1 and B.1.617.2 spike (Fig. 2h, 
i and Extended Data Fig. 3a, b) using the PV system, infecting Calu-3 lung 
cells expressing endogenous levels of angiotensin-converting enzyme 
2 (ACE2) and TMPRSS2 (Fig. 2j), as well as other cells transduced or tran-
siently transfected with ACE2 and TMPRSS2 (Extended Data Fig. 3b). 
B.1.617 spike proteins were present predominantly in the cleaved form, 
in contrast to WT (Fig. 2h, i and Extended Data Fig. 3c). We observed 1 
log increased entry efficiency for both B.1.617.1 and B.1.617.2 over WT 
(Extended Data Fig. 3b).
The B.1.617.1 variant was detected before B.1.617.2 in India, and the 
reasons for B.1.617.2 outcompeting B.1.617.1 are unknown. B.1.617.2 had 
an entry advantage compared with B.1.617.1 in Calu-3 cells bearing endog-
enous receptors (Fig. 2j). We confirmed higher infectivity of B.1.617.2 
using live virus isolates in Calu-3 cells (Fig. 2k), offering a parsimonious 
explanation for the epidemiologic growth advantage of B.1.617.2.
B.1.617.2 vaccine breakthrough infection
We hypothesized that vaccine effectiveness against B.1.617.2 would 
be compromised relative to that against other circulating variants. 
Vaccination of health care workers (HCWs) started in early 2021 with 
the ChAdOx1 vaccine (Covishield). During the wave of infections in 
March and April, symptomatic SARS-CoV-2 was confirmed in 30 vac-
cinated staff members among a workforce of 3,800 at a single tertiary 
centre in Delhi. Genomic data from India and Delhi suggested B.1.1.7 
dominance (Fig. 1a and Extended Data Fig. 4a), with growth of B.1.617 
during March 2021. Short-read sequencing14 of symptomatic non-fatal 
infections in the HCW outbreak revealed that the majority were B.1.617.2 
with a range of other B lineage viruses (Fig. 3a). Phylogenetic analysis 
demonstrated a group of highly related, and in some cases, geneti-
cally indistinct sequences that were sampled within 1 or 2 days of each 
other (Fig. 3a and Extended Data Fig. 4b). We next looked in greater 
detail at the vaccination history of affected individuals. Nearly all had 
received two doses at least 21 days previously. We obtained similar 
data on vaccine breakthrough infections in two other health facili-
ties in Delhi with 1,100 and 4,000 HCW staff members, respectively 
(Fig. 3b, c and Extended Data Fig. 4c, d). In hospital 2, there were 118 
sequences, representing more than 10% of the workforce over a 4-week 
period. After filtering, we reconstructed phylogenies using 66 with 
high-quality whole-genome coverage >95%. In hospital 3, there were 
70 symptomatic infections, with 52 high-quality genomes used for 
inferring phylogenies after filtering.
Across the three centres, we noted that the median age and duration of 
infection of those infected with B.1.617.2 versus non-B.1.617.2 were similar 
(Extended Data Table 3), with no evidence that B.1.617.2 was associated 
with higher risk of hospitalization (Extended Data Table 3). Next we evalu-
ated the effect of B.1.617.2 on vaccine effectiveness against symptomatic 
infection in the HCWs, compared with other lineages. We used multi-
variable logistic regression to estimate the odds ratio of testing positive 
with B.1.617.2 versus non-B.1.617.2 in vaccinated relative to unvaccinated 
individuals15, adjusting for age, sex and hospital. The adjusted odds ratio 
for B.1.617.2 relative to non-B.1.617.2 was 5.45 (95% confidence interval 
1.39–21.4, P = 0.018) for two vaccine doses (Extended Data Table 4).
Discussion
Here we have combined in vitro experimentation and molecular epidemi-
ology to propose that increased replication fitness and reduced sensitiv-
ity of SARS-CoV-2 B.1.617.2 to neutralizing antibodies have contributed 
to the recent rapid increase of B.1.617.2, compared with B.1.1.7 and other 
lineages such as B.1.617.1, despite high vaccination rates in adults and/
or high prevalence of prior infection16. These data are consistent with 
modelling analyses that support combination of immune evasion and 
higher transmissibility as likely drivers of the increase in Delta in Delhi17.
We demonstrate evasion of neutralizing antibodies by a B.1.617.2 
live virus with sera from convalescent patients, as well as sera from 
individuals vaccinated with two different vaccines, one based on an 
adenovirus vector (ChAdOx1) and the other mRNA based (BNT162b2). 
The reduced efficacy for imedevimab against B.1.617.2 shown here 
could translate to compromised clinical efficacy or possible selection 
of escape variants where there is immune compromise and chronic 
SARS-CoV-2 infection with B.1.617.2 (ref. 18).
It is important to consider that increased infectivity at mucosal 
surfaces and cell–cell fusion and spread19 may also facilitate ‘evasion’ 
from antibodies20. Indeed, our work also shows that B.1.617.2 had a 
fitness advantage compared with B.1.1.7 across physiologically relevant 
systems including HAE and three-dimensional airway organoids10 where 
cell-free and cell–cell infection are likely to be occurring together. These 
data support the notion of higher infectiousness of B.1.617.2, either 
due to higher viral burden or higher particle infectivity, resulting in 
higher probability of person-to-person transmission. We noted that 
B.1.617.2 live virus particles contained a higher proportion of cleaved 
spike than B.1.1.7, and postulated that this is involved in the mechanism 
of increased infectivity. This hypothesis was supported by our observa-
tion that PV particles bearing B.1.617.2 spike demonstrated significantly 
enhanced entry into a range of target cells.
Finally, we report ChAdOx1 vaccine breakthrough infections in HCWs 
at three Delhi hospitals, demonstrating reduced vaccine effectiveness 
against B.1.617.2. Therefore, strategies to boost vaccine responses 
against variants are warranted and attention to infection control pro-
cedures is needed in the post-vaccination era.
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Serum samples and ethical approval
Ethical approval for the study of vaccine-elicited antibodies in sera 
from vaccinees was obtained from the East of England – Cambridge 
Central Research Ethics Committee Cambridge (REC ref. 17/EE/0025). 
Use of convalescent sera had ethical approval from the South Central 
- Berkshire B Research Ethics Committee (REC ref. 20/SC/0206; IRAS 
283805). Studies involving HCWs (including testing and sequencing 
of respiratory samples) were reviewed and approved by The Institu-
tional Human Ethics Committees of the National Centre for Disease 
Control (NCDC) and CSIR-IGIB(NCDC/2020/NERC/14 and CSIR-IGIB/
IHEC/2020-21/01). Participants provided informed consent.
Sequencing quality control and phylogenetic analysis
Three sets of fasta consensus sequences were obtained from three 
separate hospitals in Delhi, India. Initially, all sequences were con-
catenated into a multi-fasta file and then aligned to the reference 
strain MN908947.3 (Wuhan-Hu-1) with mafft v4.487 (ref. 21) using the 
--keeplength and --addfragments options. Following this, all sequences 
were passed through Nextclade v0.15 (https://clades.nextstrain.org/) to 
determine the number of gap regions. This was noted and all sequences 
were assigned a lineage with Pangolin v3.1.5 (ref. 22) and pangoLEARN 
(dated 15 June 2021). Sequences that could not be assigned a lineage 
were discarded. After assigning lineages, all sequences with more than 
5% N regions were also excluded.
Phylogenies were inferred using maximum likelihood in IQTREE v2.1.4 
(ref. 23) using a GTR + R6 model with 1,000 rapid bootstraps. The inferred 
phylogenies were annotated in R v4.1.0 using ggtree v3.0.2 (ref. 24) and 
rooted on the SARS-CoV-2 reference sequence (MN908947.3). Nodes 
were arranged in descending order and lineages were annotated on the 
phylogeny as coloured tips, alongside a heatmap defining the number 
of ChAdOx1 vaccine doses received by each patient.
Structural analyses
The PyMOL Molecular Graphics System v.2.4.0 (https://github.com/
schrodinger/pymol-open-source/releases) was used to map the loca-
tion of the mutations defining the Delta lineage (B.1.617.2) onto the 
closed-conformation spike protein (PDB: 6ZGE)25.
Statistical analyses
Vaccine breakthrough infections in HCWs. Descriptive analyses of 
demographic and clinical data are presented as median and interquar-
tile range or mean and standard deviation (s.d.) when continuous and 
as frequency and proportion (%) when categorical. The differences in 
continuous and categorical data were tested using the Wilcoxon rank 
sum test or t-test and chi-square test, respectively. The association 
between the Ct value and the SARS-CoV-2 variant was examined using 
linear regression. Variants as the dependent variable were categorized 
into two groups: B.1.617.2 variant and non-B.1.617.2 variants. The follow-
ing covariates were included in the model irrespective of confounding: 
age, sex, hospital and interval between symptom onset and nasal swab 
PCR testing.
Vaccine effectiveness. To estimate vaccine effectiveness for the 
B.1.617.2 variant relative to non-B.1.617.2 variants, we adopted a recently 
described approach15. This method is based on the premise that if the 
vaccine is equally effective against B.1.617.2 and non-B.1.617.2 variants, 
a similar proportion of cases with each variant would be expected in 
both vaccinated and unvaccinated cases. This approach overcomes the 
issue of higher background prevalence of one variant over the other. 
We determined the proportion of individuals with the B.1.617.2 variant 
relative to all other circulating variants by vaccination status. We then 
used logistic regression to estimate the odds ratio of testing positive 
with B.1.617.2 in vaccinated compared with unvaccinated individuals. 
The final regression model was adjusted for age as a continuous vari-
able, and sex and hospital as categorical variables. Model sensitivity and 
robustness to inclusion of these covariates was tested by an iterative 
process of sequentially adding the covariates to the model and examin-
ing the impact on the odd ratios and confidence intervals until the final 
model was constructed (Extended Data Table 4). The R2 measure, as pro-
posed by McFadden26, was used to test the fit of different specifications 
of the same model regression. This is was performed by sequential ad-
dition of the variables adjusted for including age, sex and hospital until 
the final model was constructed. In addition, the absolute difference 
in the Bayesian information criterion was estimated. The McFadden 
R2 measure of final model fitness was 0.11, indicating reasonable model 
fit. The addition of age, sex and hospital in the final regression model 
improved the measured fitness. However, the absolute difference in the 
Bayesian information criterion was 13.34 between the full model and 
the model excluding the adjusting variable, providing strong support 
for the parsimonious model. The fully adjusted model was nonethe-
less used as the final model as the sensitivity analyses (Extended Data 
Table 4) showed robustness to the addition of the covariates.
Neutralization titre analyses. The neutralization by vaccine-elicited 
antibodies after two doses of the BNT162b2 or ChadOx1 vaccines was 
determined by infections in the presence of serial dilutions of sera as 
described below. The ID50 for each group was summarized as a GMT, 
and statistical comparisons between groups were performed with 
Mann–Whitney or Wilcoxon ranked sign tests. Statistical analyses were 
performed using Stata v13 and Prism v9.
PV experiments
Cells. HEK 293T CRL-3216, HeLa-ACE2 (gift from James Voss) and Vero 
CCL-81 cells were maintained in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal calf serum (FCS), 100 U ml−1 peni-
cillin and 100 mg ml−1 streptomycin. All cells were regularly tested and 
found to be mycoplasma free. H1299 cells were a gift from Simon Cook. 
Calu-3 cells were a gift from Paul Lehner. A549 ACE2/TMPRSS2 (ref. 27) 
cells were a gift from Massimo Palmerini. Vero E6 ACE2/TMPRSS2 cells 
were a gift from Emma Thomson.
PV preparation for testing against vaccine-elicited antibodies 
and cell entry. Plasmids encoding the spike protein of SARS-CoV-2 
D614 with a carboxy-terminal 19-amino-acid deletion with D614G were 
used. Mutations were introduced using the QuikChange Lightning 
Site-Directed Mutagenesis kit (Agilent) following the manufacturer’s 
instructions. Preparation of the B.1.1.7 S-expressing plasmid was de-
scribed previously, but in brief, it was generated by stepwise mutagen-
esis. Viral vectors were prepared by transfection of 293T cells by using 
Fugene HD transfection reagent (Promega). 293T cells were transfected 
with a mixture of 11 µl Fugene HD, 1 µg pCDNAΔ19 spike–HA, 1 µg p8.91 
human immunodeficiency virus 1 (HIV-1) gag–pol expression vector 
and 1.5 µg pCSFLW (expressing the firefly luciferase reporter gene 
with the HIV-1 packaging signal). Viral supernatant was collected at 
48 and 72 h after transfection, filtered through a 0.45-µm filter and 
stored at −80 °C as previously described. Infectivity was measured by 
luciferase detection in target 293T cells transfected with TMPRSS2 and 
ACE2, Vero E6 ACE2/TMPRSS2, Calu-3, A549 ACE2/TMPRSS2, H1299 
and HeLa-ACE2 cells.
Standardization of virus input by SYBR Green-based 
product-enhanced PCR assay. The reverse transcriptase (RT) activ-
ity of virus preparations was determined by quantitative PCR (qPCR) 
using a SYBR Green-based product-enhanced PCR assay as previously 
described28. In brief, tenfold dilutions of virus supernatant were lysed 
in a 1:1 ratio in a 2× lysis solution (made up of 40% glycerol (v/v), 0.25% 
Triton X-100 (v/v), 100 mM KCl, RNase inhibitor 0.8 U ml−1, Tris HCl 
100 mM, buffered to pH 7.4) for 10 min at room temperature.
A 12-µl volume of each sample lysate was added to 13 µl of a SYBR 
Green master mix (containing 0.5 µM MS2-RNA forward and reverse 
primers, 3.5 pmol ml−1 MS2-RNA and 0.125 U µl−1 Ribolock RNAse inhibi-
tor) and cycled in a QuantStudio. Relative amounts of RT activity were 
determined as the rate of transcription of bacteriophage MS2 RNA, with 
absolute RT activity calculated by comparing the relative amounts of 
RT activity with an RT standard of known activity.
Viral isolate comparison between B.1.617.1 and B.1.617.2
Cell culture. Vero E6 TMPRSS2  cells (an African green monkey 
(Chlorocebus sabaeus) kidney cell line; JCRB1819)29 were maintained 
in DMEM (low glucose) (Wako, catalogue no. 041-29775) containing 
10% FCS, G418 (1 mg ml−1; Nacalai Tesque, catalogue no. G8168-10ML) 
and 1% antibiotics (penicillin and streptomycin (P/S)).
Calu-3 cells (a human lung epithelial cell line; ATCC HTB-55) were 
maintained in minimum essential medium Eagle (Sigma-Aldrich, 
catalogue no. M4655-500ML) containing 10% FCS and 1% PS.
SARS-CoV-2 B.1.617.1 versus B.1.617.2 experiment. Two viral isolates 
belonging to the B.1.617 lineage, B.1.617.1 (GISAID ID: EPI_ISL_2378733) 
and B.1.617.2 (GISAID ID: EPI_ISL_2378732), were isolated from 
SARS-CoV-2-positive individuals in Japan. Briefly, 100 µl of the naso-
pharyngeal swab obtained from SARS-CoV-2-positive individuals was 
inoculated into Vero E6 TMPRSS2 cells in a biosafety level 3 laboratory. 
After incubation at 37 °C for 15 min, a maintenance medium (Eagle’s 
minimum essential medium (FUJIFILM Wako Pure Chemical Corpora-
tion, catalogue no. 056-08385) including 2% FCS and 1% PS) was added, 
and the cells were cultured at 37 °C under 5% CO2. The cytopathic effect 
(CPE) was confirmed under an inverted microscope (Nikon), and the 
viral load of the culture supernatant in which CPE was observed was 
confirmed by real-time PCR with reverse transcription (RT–PCR). To 
determine viral genome sequences, RNA was extracted from the culture 
supernatant using the QIAamp viral RNA mini kit (Qiagen, catalogue no. 
52906). A cDNA library was prepared using NEB Next Ultra RNA Library 
Prep Kit for Illumina (New England Biolab, catalogue no. E7530), and 
whole-genome sequencing was performed using a Miseq instrument 
(Illumina).
To prepare the working virus, 100 µl of the seed virus was inoculated 
into Vero E6 TMPRSS2 cells (5,000,000 cells in a T-75 flask). At 1 h after 
infection, the culture medium was replaced with DMEM (low glucose) 
(Wako, catalogue no. 041-29775) containing 2% FBS and 1% PS; at 2–3 
days post-infection, the culture medium was collected and centrifuged, 
and the supernatants were collected as the working virus.
The titre of the prepared working virus was measured as 50% tissue 
culture infectious dose (TCID50). Briefly, 1 day before infection, Vero 
E6 TMPRSS2 cells (10,000 cells per well) were seeded into a 96-well 
plate. Serially diluted virus stocks were inoculated onto the cells and 
incubated at 37 °C for 3 days. The cells were observed by microscopy 
to judge the CPE appearance. The TCID50 ml
−1 value was calculated with 
the Reed–Muench method30.
One day before infection, 20,000 Calu-3 cells were seeded into a 
96-well plate. SARS-CoV-2 (200 TCID50) was inoculated and incubated 
at 37 °C for 1 h. The infected cells were washed, and 180 µl of culture 
medium was added. The culture supernatant (10 µl) was collected at 
indicated time points and used for real-time RT–PCR to quantify the 
viral RNA copy number.
Real-time RT–PCR. Real-time RT–PCR was performed as previously 
described31,32. In brief, 5 µl of culture supernatant was mixed with 5 µl 
of 2× RNA lysis buffer (2% Triton X-100, 50 mM KCl, 100 mM Tris HCl 
(pH 7.4), 40% glycerol, 0.8 U µl−1 recombinant RNase inhibitor (Takara, 
catalogue no. 2313B)) and incubated at room temperature for 10 min. 
RNase-free water (90 µl) was added, and the diluted sample (2.5 µl) was 
used as the template for real-time RT–PCR performed according to 
the manufacturer’s protocol using the One Step TB Green PrimeScript 
PLUS RT–PCR kit (Takara, catalogue no. RR096A) and the following 
primers: forward N, 5′-AGCCTCTTCTCGTTCCTCATC AC-3′; and reverse 
N, 5′-CCGCCATTGCCAGCCATT C-3′. The copy number of viral RNA was 
standardized with a SARS-CoV-2 direct detection RT–qPCR kit (Takara, 
catalogue no. RC300A). The fluorescent signal was acquired using 
a QuantStudio 3 Real-Time PCR system (Thermo Fisher Scientific), a 
CFX Connect Real-Time PCR Detection System (Bio-Rad) or a 7500 Real 
Time PCR System (Applied Biosystems).
Virus growth kinetics in HAE cells. Primary nasal HAE cells at the air–
liquid interface were purchased from Epithelix and the basal MucilAir 
medium (Epithelix) was changed every 2–3 days for maintenance of 
HAE cells. All dilution of viruses, wash steps and collection steps were 
carried out with OptiPRO serum-free medium (SFM; Life Technolo-
gies) containing 2× GlutaMAX (Gibco). All wash and collection steps 
were performed by addition of 200 µl SFM to the apical surface and 
incubation for 10 min at 37 °C before removing SFM. To infect cells, 
the basal medium was replaced, and the apical surface of the HAE cells 
was washed once with SFM to remove mucus before addition of virus to 
triplicate wells. Cells were infected at a multiplicity of infection (MOI) 
of 1 × 104 genome copies of virus per cell based on E gene qRT–PCR. The 
cells were incubated with the inoculum for 1 h at 37 °C before washing 
their apical surface twice and retaining the second wash as the sample 
for 0 hpi. A single apical wash was performed to collect virus at 24, 48 
and 71 h time points. Isolates used were B.1.617.2 isolate no. 60 hCoV-
19/England/SHEF-10E8F3B/2021 (EPI_ISL_1731019), B.1.617.2 isolate 
no. 285 hCoV-19/England/PHEC-3098A2/2021 (EPI_ISL_2741645) and 
B.1.1.7 isolate no. 7540 SMH2008017540 (confirmed B.1.1.7 in-house 
but not yet available on GISAID).
Titration of outputs from HAE infections. For quantifying genome 
copies in the virus inputs and in the supernatant collected from HAE 
cells, RNA was extracted using the QIAsymphony DSP Virus/Patho-
gen Mini Kit on the QIAsymphony instrument (Qiagen). qRT–PCR was 
then performed using the AgPath RT–PCR (Life Technologies) kit on 
a QuantStudio(TM) 7 Flex System with the primers for SARS-CoV-2 E 
gene used previously33 . A standard curve was also generated using 
dilutions of viral RNA of known copy number to allow quantification of 
E gene copies in the samples from Ct values. E gene copies per millilitre 
of original virus supernatant were then calculated.
For measuring infectious virus in samples collected from HAE cells, 
plaque assays were carried out by performing serial log dilutions 
of supernatant in DMEM, 1% NEAA and 1% P/S and inoculating onto 
PBS-washed Vero cells, incubating for 1 h at 37 °C, removing inoculum 
and overlaying with 1× MEM, 0.2% (w/v) BSA, 0.16% (w/v) NaHCO3, 
10 mM HEPES, 2 mM l-glutamine, 1× P/S, 0.6% (w/v) agarose. Plates 
were incubated for 3 days at 37 °C before the overlay was removed 
and cells were stained for 1 h at room temperature in crystal violet 
solution.
Lung organoid infection by replication-competent SARS-CoV-2 
isolates. Airway epithelial organoids were prepared as previously 
reported10. For viral infection, primary organoids were passaged and 
incubated with SARS-CoV-2 in suspension at an MOI of 1 for 2 h. Subse-
quently, the infected organoids were washed twice with PBS to remove 
the viral particles. Washed organoids were plated in 20-µl Matrigel 
domes, cultured in organoid medium and collected at different time 
points.
Cells were lysed 24 and 48 h post-infection and total RNA was iso-
lated. cDNA was synthesized and qPCR was used to quantify copies 
of the nucleoprotein gene in samples. A standard curve was prepared 
using SARS-CoV-2 Positive Control plasmid encoding full nucleocap-
sid protein (N gene; NEB) and used to quantify copies of the N gene 
in organoid samples. 18S ribosomal RNA was used as a housekeeping 
gene to normalize sample-to-sample variation.
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Western blotting. Cells were lysed and supernatants were collected 48 h 
post transfection. Purified virions were prepared by collecting superna-
tants and passing them through a 0.45-µm filter. Clarified supernatants 
were then loaded onto a thin layer of 8.4% OptiPrep density gradient 
medium (Sigma-Aldrich) and placed in a TLA55 rotor (Beckman Coul-
ter) for ultracentrifugation for 2 h at 20,000 r.p.m. The pellet was then 
resuspended for western blotting. Cells were lysed with cell lysis buffer 
(Cell Signaling), treated with Benzonase nuclease (70664 Millipore) and 
boiled for 5 min. Samples were then run on 4–12% Bis Tris gels and trans-
ferred onto nitrocellulose or polyvinylidene fluoride membranes using 
an iBlot or semidry system (Life Technologies and Bio-Rad, respectively).
Membranes were blocked for 1 h in 5% non-fat milk in PBS + 0.1% Tween-
20 (PBST) at room temperature with agitation, incubated in primary anti-
body (anti-SARS-CoV-2 spike, which detects the S2 subunit of SARS-CoV-2 
S (Invitrogen, PA1-41165), anti-GAPDH (Proteintech) or anti-p24 (NIBSC)) 
diluted in 5% non-fat milk in PBST for 2 h at 4 °C with agitation, washed 
four times in PBST for 5 min at room temperature with agitation and 
incubated in secondary antibodies anti-rabbit HRP (1:10,000, Invitrogen 
31462)and anti-β-actin HRP (1:5,000; sc-47778) diluted in 5% non-fat milk 
in PBST for 1 h with agitation at room temperature. Membranes were 
washed four times in PBST for 5 min at room temperature and imaged 
directly using a ChemiDoc MP imaging system (Bio-Rad).
Virus infection for virion western blotting. Vero E6 ACE2/TMPRSS2 
cells were infected with an MOI of 1 and incubated for 48 h. Superna-
tant was cleared by a 5-min spin at 300g and then precipitated with 
10% PEG6000 (4 h at room temperature). Pellets were resuspended 
directly in Laemmli buffer with 1 mM dithiothreitol, treated with 
Benzonase nuclease (70664 Millipore) and sonicated before loading 
for gel electrophoresis
Serum pseudotype neutralization assay
Spike pseudotype assays have been shown to have similar characteris-
tics to neutralization testing using fully infectious WT SARS-CoV-2 (34). 
Virus neutralization assays were performed on 293T cells tran-
siently transfected with ACE2 and TMPRSS2 using SARS-CoV-2 spike 
PV expressing luciferase35. PV was incubated with serial dilutions 
of heat-inactivated human serum samples or convalescent plasma 
in duplicate for 1 h at 37 °C. Virus- and cell-only controls were also 
included. Then, freshly trypsinized 293T ACE2/TMPRSS2-expressing 
cells were added to each well. Following a 48-h incubation in a 
5% CO2 environment at 37 °C, the luminescence was measured using 
the Steady-Glo Luciferase assay system (Promega).
Neutralization assays for convalescent plasma. Convalescent 
serum samples from HCWs at St Mary’s Hospital at least 21 days since 
PCR-confirmed SARS-CoV-2 infection were collected in May 2020 as 
part of the REACT2 study.
Convalescent human serum samples were inactivated at 56 °C for 
30 min, and replicate serial twofold dilutions (n = 12) were mixed with an 
equal volume of SARS-CoV-2 (100 TCID50; total volume 100 µl) at 37 °C 
for 1 h. Vero E6 ACE2/TMPRSS2 cells were subsequently infected with 
serial fold dilutions of each sample for 3 days at 37 °C. Virus neutrali-
zation was quantified via crystal violet staining and scoring for CPE. 
Each run included 1:5 dilutions of each test sample in the absence of 
virus to ensure virus-induced CPE in each titration. Back titrations of 
SARS-CoV-2 infectivity were performed to demonstrate infection with 
~100 TCID50 in each well.
Vaccinee serum neutralization, live virus assays
 Vero E6 ACE2/TMPRSS2 cells were seeded at a cell density of 2 × 104 per 
well in a 96-well plate 24 h before infection. Serum was titrated start-
ing at a final 1:10 dilution, with WT (SARS-CoV-2/human/Liverpool/
REMRQ0001/2020), B.1.1.7 or B.1.617.2 virus isolates being added at an 
MOI of 0.01. The mixture was incubated for 1 h before adding to cells. 
The plates were fixed with 8% PFA 72 h post-infection and stained with 
Coomassie blue for 20 min. The plates were washed in water and dried 
for 2 h. 1% SDS solution was then added to wells and the staining intensity 
was measured using FLUOstar Omega (BMG Labtech). The percentage 
of cell survival was determined by comparing the intensity of stain-
ing with that in an uninfected well. A nonlinear sigmoidal 4PL model 
(Graphpad Prism 9.1.2) was used to determine the ID50 for each serum.
Vesicular stomatitis virus pseudovirus generation for 
monoclonal antibody assays
Replication-defective vesicular stomatitis virus (VSV) pseudovirus 
expressing SARS-CoV-2 spike proteins corresponding to the different 
variants of concern were generated as previously described with some 
modifications36. Lenti-X 293T cells (Takara, 632180) were seeded in 
10-cm2 dishes at a density of 5 × 106 cells per dish and the following day 
transfected with 10 µg of WT or B.1.617.2 spike expression plasmid with 
TransIT-Lenti (Mirus, 6600) according to the manufacturer’s instruc-
tions. One day post-transfection, cells were infected with VSV–luc (VSV 
G) with an MOI of 3 for 1 h, rinsed three times with PBS containing Ca2+/
Mg2+, and then incubated for an additional 24 h in complete medium 
at 37 °C. The cell supernatant was clarified by centrifugation, filtered 
(0.45 µm), aliquoted and frozen at −80 °C.
PV neutralization assay for monoclonal antibody. Vero E6 cells ex-
pressing TMPRSS2 or not were grown in DMEM supplemented with 10% 
FBS and seeded into white 96-well plates (PerkinElmer, 6005688) at a 
density of 20 thousand cells per well. The next day, monoclonal anti-
bodies were serially diluted in pre-warmed complete medium, mixed 
with WT or B.1.617.2 pseudoviruses and incubated for 1 h at 37 °C in 
round-bottom polypropylene plates. Medium from cells was aspirated 
and 50 µl of virus–monoclonal antibody complexes was added to cells 
and then incubated for 1 h at 37 °C. An additional 100 µl of pre-warmed 
complete medium was then added on top of complexes, and cells were 
incubated for an additional 16–24 h. Conditions were tested in duplicate 
wells on each plate and at least six wells per plate contained untreated 
infected cells (defining the 0% of neutralization, MAX relative light unit 
(RLU) value) and infected cells in the presence of S2E12 and S2X259 at 
25 µg ml−1 each (defining the 100% of neutralization, MIN RLU value). 
Medium containing virus–monoclonal antibody complexes was then 
aspirated from cells and 50 µl of a 1:2 dilution of SteadyLite Plus (Perkin 
Elmer, 6066759) in PBS with Ca2+ and Mg2+ was added to cells. Plates were 
incubated for 15 min at room temperature and then analysed on the 
Synergy-H1 (Biotek). The average RLU value for untreated infected wells 
(MAX RLUave) was subtracted by the average MIN RLU (MIN RLUave) value 
and used to normalize the percentage of neutralization of individual 
RLU values of experimental data according to the following formula: 
(1 –  (RLUx – MIN RLUave)/(MAX RLUave – MIN RLUave)) × 100. Data were 
analysed and visualized with Prism (Version 9.1.0). IC50 values were 
calculated from the interpolated value from the log[inhibitor] versus 
response, using variable slope (four parameters) nonlinear regression 
with an upper constraint of ≤100, and a lower constraint equal to 0. Each 
neutralization assay was conducted on two independent experiments 
(that is, biological replicates), with each biological replicate contain-
ing a technical duplicate. IC50 values across biological replicates are 
presented as arithmetic mean ± s.d. The loss or gain of neutralization 
potency across spike variants was calculated by dividing the variant 
IC50 by the WT IC50 within each biological replicate, and then visualized 
as arithmetic mean ± s.d.
Plasmids for split GFP system to measure cell–cell fusion. pQCXIP‐
BSR‐GFP11 and pQCXIP‐GFP1–10 were from Yutaka Hata37 (Addgene 
plasmid no. 68716; http://n2t.net/addgene:68716; RRID:Addgene_68716 
and Addgene plasmid no. 68715; http://n2t.net/addgene:68715; 
RRID:Addgene_68715).
Generation of GFP1–10 or GFP11 lentiviral particles. Lentiviral par-
ticles were generated by co-transfection of Vero cells with pQCXIP‐
BSR‐GFP11 or pQCXIP‐GFP1–10 as previously described38. Supernatant 
containing virus particles was collected after 48 and 72 h, 0.45-µm 
filtered, and used to infect 293T or Vero cells to generate stable cell 
lines. 293T and Vero cells were transduced to stably express GFP1–10 
or GFP11, respectively, and were selected with 2 µg ml−1 puromycin.
Cell–cell fusion assay. The cell–cell fusion assay was carried out as 
previously described38,39 but using a split GFP system. Briefly, Vero 
GFP1–10 and Vero-GFP11 cells were seeded at 80% confluence in a 1:1 
ratio in a 24-well plate the day before. Cells were co-transfected with 
0.5 µg of spike expression plasmids in pCDNA3 using Fugene 6 fol-
lowing the manufacturer’s instructions (Promega). Cell–cell fusion 
was measured using an Incucyte and determined as the proportion of 
green area to total phase area. Data were then analysed using Incucyte 
software. Graphs were generated using Prism 8 software.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
All SARS-CoV-2 fasta consensus sequence files used in this analysis are 
available from https://gisaid.org (with accession numbers: hospital 1, 
EPI_ISIL_1970102–EPI_ISIL_17010116; hospital 2, EPI_ISIL_2461070–EPI_
ISIL_2955768; hospital 3, EPI_ISL_2955782–EPI_ISL_3066853) or https://
github.com/Steven-Kemp/hospital_india/tree/main/consensus_fasta. 
All consensus sequence data have also been submitted to NCBI GenBank 
and can be found with the accession numbers MZ724413–MZ724540.
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Extended Data Fig. 1 | See next page for caption.
Extended Data Fig. 1 | Delta variant B.1.617.2 shows reduced sensitivity to 
monoclonal antibodies. Neutralisation by a panel of NTD- and RBD-
specific mAbs against WT and B.1.617.2 mutant SARS-CoV-2 pseudotyped 
viruses. a. Neutralisation of WT D614 (black) and B.1.617.2 mutant (blue) 
pseudotyped SARS-CoV-2-VSV by 6 selected mAbs from one representative 
experiment out of 2 independent experiments. S2X333 is an NTD-specific 
mAb, S2D97, S2E12 and S2X58 are RBM-specific mAbs, while S2X35 and S2X305 
are non-RBM mAbs. b. Neutralisation of WT and B.1.617.2 VSV by 
38 mAbs targeting NTD (n = 3), RBM (n = 26, including 5 clinical stage mAb) and 
non-RBM (n = 9). Shown are the mean IC50 values (ng/ml) from 2 independent 
experiments. Non-neutralising IC50 titers were set at 104 ng/ml. c. 
Neutralisation shown as mean IC50 values (upper panel) and average fold 
change of B.1.617.2 relative to WT (lower panel) of 38 mAbs tested in 2 
independent experiments (including 5 clinical-stage mAbs), tested using Vero 
E6 cells expressing TMPRSS2. d–e, Neutralisation of WT D614 (black) and 
B.1.617.2 mutant (blue/red) pseudotyped SARS-CoV-2-VSV by 5 clinical-stage 
mAbs using Vero E6 cells expressing TMPRSS2 (d) or not (e). Shown is one 
representative experiment out of 2 independent experiments.
Article
Extended Data Fig. 2 | Spike cleavage in B.1.617.2 virions compared to 
B.1.1.7. and spike mediated cell-cell fusion. a. Representative western blot 
analysis of spike and nucleoprotein present in SARS-CoV-2 particles from 
the indicated viruses produced in Vero E6 ACE2/TMPRSS2 cells 48 h post 
infection. The arrowhead identifies the S2 subunit. b. Quantification of cleaved 
and full-length spike of the indicated viruses. c. Schematic of cell-cell fusion 
assay. d. Reconstructed images at 10 h of GFP positive syncytia 
formation. Scale bars represent 400 mm. e. western blot of cell lysates 48 h 
after transfection of spike plasmids.f,g. Quantification of cell-cell fusion 
kinetics showing percentage of green area to total cell area over time. Mean is 
plotted with error bars representing SEM. h. Comparison of impact of post 
vaccine sera (n = 2) on PV neutralisation (top) and cell-cell fusion (bottom), 
comparing WT and Delta variant B.1.671.2. Data are representative of at least 
two independent experiments.
Extended Data Fig. 3 | B.1.617.2 spike confers increased cell entry.  
a. diagram showing mutations present in spike plasmids used for cell entry PV 
experiments b. Single round infectivity on different cell targets by spike 
B.1.617.1 and B.1.617.1 versus WT (Wuhan-1 D614G) PV produced in 293T cells. 
Data are representative of three independent experiments. Statistics were 
performed using unpaired Student t test. c. Western blotting of supernatants 
from transfected 293T probing for S2 and p24 in PV and showing no spike 
control.
Article
Extended Data Fig. 4 | Breakthrough SARS-CoV-2 infections amongst 
vaccinated health care workers (HCW). a. Case frequencies of five most 
commonly occurring SARS CoV-2 lineages over a six week period from March to 
April 2021 for Delhi b,c,d. case frequency graph for hospital 1, 2 and 3 
respectively by date of testing. e. Comparison of IgG antibody titres between a 
control group of vaccinated individuals receiving two doses of ChadOx-1 who 
have not been infected with SARS-CoV-2, with vaccinated healthcare workers 
who had received two doses and subsequently tested positive for SARS-CoV-2. 
f. Ct values in nose/throat swabs from HCW testing positive by hospital. Bars 
represent Mean and 95% CI. Ct values were compared using the Student t test.
Extended Data Table 1 | Demographic information for individuals undergoing two dose SARS-CoV-2 vaccination with 
ChAdOx-1 or BNT162b2
aChi-square test, b Mann-Whitney test.
Article
Extended Data Table 2 | Monoclonal antibodies used in neutralisation assays against pseudotyped virus bearing spike from 
WT (Wuhan-1 D614) or B.1.617.2
* in TMPRSS2 expressing VeroE6 cells.
Extended Data Table 3 | Data on SARS-CoV-2 infections in three hospitals with near universal staff vaccination during first 
half of 2021
a Wilcoxon rank-sum test. bChi square test. c111 of 112 available. d11 of 112. e2 of 20. f63 of 112. g 12 of 20. †Vaccine status missing for 1 of 132. *Hospitalisation data is unavailable from Hospital 1. IQR- 
inrerquartile range, GMT- geometric mean titre. CI- confidence interval.
Article
Extended Data Table 4 | Relative recei1 vaccine effectiveness against B1.617.2 v non- B1.617.2: Upper Table: Odds ratios for 
detection of B.1.617.2 relative to non-B.1.617.2 in vaccinated compared to unvaccinated individuals in multi-variable logistic 
regression
Bottom table shows sensitivity of model to iterative addition of covariates. OR; odds ratio aOR; Adjusted odds ratio.
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The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Software and code
Policy information about availability of computer code
Data collection Graphad Prism v9.0.2 were used to produce figures. 
Mafft v7.475 was used for multiple sequence alignments. 
IQTREE and ModelFinder v2.1.4 was used to infer maximum-likelihood phylogenies. 
R v4.1.0 and ggplot package v3.3.3 were used to annotate phylogenies.
Data analysis NextClade server v0.14.4 and Pangolin v3.0.5 were used to assign lineages to sequences.  
Pymol Graphics Suite v2.4.0 was used to visualize and annotate 3D protein structures 
Stata v13 was used for statistical analyses.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and 
reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Sequences from SARS-CoV-2 were obtained from GISAID database (https://gisaid.org/) using the filters and search parameters defined in the methods section. 
Structural models were obtained from the Protein Data Bank (PDB) https://www.rcsb.org/.  
All fasta consensus sequences files donated by collaborators are freely available from Gisaid (https://gisaid.org) with accession numbers as follows: Hospital 1: 
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EPI_ISIL_1970102 – EPI_ISIL_17010116; Hospital 2: EPI_ISIL_2461070 – EPI_ISIL_2955768; Hospital 3: EPI_ISL_2955782 - EPI_ISL_3066853; or from https://
github.com/Steven-Kemp/hospital_india/tree/main/consensus_fasta. A list of anonymised IDs and their corresponding Gisaid accession can be found at the github 
link. All consensus sequence data was additionally submitted to NCBI Genbank and can be found with the following accession numbers: MZ724413 - MZ724540.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size This is a descriptive study of an outbreak of SARS-CoV-2 in 3 hospitals and so a sample size is not appropriate. 
Data exclusions For sequencing data, consensus fasta files were excluded, as described in the methods section, based on poor coverage of the genomes.
Replication Experiments were done in technical duplicates and each experiment was repeated.
Randomization Not applicable as this is not an intervention study.
Blinding Patients were pseudoanonymised at point of receiving all data from collaborators. All reported data in phylogenies are blinded and only show 
values and lineage assignments.
Reporting for specific materials, systems and methods
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Antibodies used anti-SARS-CoV-2 Spike (Invitrogen, PA1-41165, 1:5,000) 
anti-GAPDH (Proteintech,60004, 1:5,000) 
anti-p24 (NIBSC, ARP365 and ARP366, 1:500; ARP313, 1in10,000) 
anti-rabbit HRP (Cell Signaling, 7074S, 1:3,000) 
anti-b-actin HRP (Abcam, ab8226, 1:10, 000)
Validation Validation was conducted by manufacturers prior to sale. No further validation was undertaken.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) HeLa ACE2 cells were donated by kind request from James Voss as noted in the methods section.  
HEK 293T CRL-3216 cells from ATCC were used for transfection work.  
H1299 cells were a gift from Simon Cook as noted in methods.  
Calu-3 cells were a gift from Paul Lehner as mentioned. 
A549 ACE2T/TMPRSS2 cells were a kind gift from Massimo Palmerini. 
Vero E6 ACE2/TMPRSS2 cells were a gift from Emma Thomson.  
HAE cells (MucilAir™) were purchased from Epithelix. 
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293T cells were purchased from Takara Bio (# 632180) 
Airway epithelial organoids were prepared and donated by Joo-Hyeon Lee as described in (10.1016/j.stem.2020.10.004)  
Authentication None of the cell lines used were authenticated.
Mycoplasma contamination All cell lines used were tested (by PCR) and were mycoplasma free.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified lines were used in this study.
Human research participants
Policy information about studies involving human research participants
Population characteristics Participants include health care workers involved in an outbreak of SARS-CoV-2 in 3 hospitals in India.  
Vaccine sera were obtained from participants involved.
Recruitment As part of routine testing, venous serum samples were collected from the participants enrolled in the NIHR BioResource 
Centre Cambridge
Ethics oversight Ethical approval for use of serum samples. Controls with COVID-19 were enrolled to the NIHR BioResource Centre Cambridge 
under ethics review board (17/EE/0025). Convalescent sera from healthcare workers at St. Marys Hospital at least 21 days 
since PCR678 confirmed SARS-CoV-2 infection were collected in May 2020 as part of the REACT2 study with ethical approval 
from South Central Berkshire B Research Ethics Committee (REC ref: 680 20/SC/0206; IRAS 283805). Studies involving health 
care workers (including testing and sequencing of respiratory samples) were reviewed and approved by The Institutional 
Human Ethics Committees of NCDC and CSIR-IGIB(NCDC/2020/NERC/14 and CSIR-IGIB/IHEC/2020-21/01). All participants 
provided informed consent. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
